223648-45-1

Basic information

• Product Name: [1-(1-carbamoyl-cyclohexylcarbamoyl)-3-methylsulfanyl-propyl]-carbamic acid tert-butyl ester
• Synonyms: [1-(1-carbamoyl-cyclohexylcarbamoyl)-3-methylsulfanyl-propyl]-carbamic acid tert-butyl ester
• CAS NO: 223648-45-1
• Molecular Weight: 373.517
• Mol File: 223648-45-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [1-(1-carbamoyl-cyclohexylcarbamoyl)-3-methylsulfanyl-propyl]-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(1-carbamoyl-cyclohexylcarbamoyl)-3-methylsulfanyl-propyl]-carbamic acid tert-butyl ester(223648-45-1)
• EPA Substance Registry System: [1-(1-carbamoyl-cyclohexylcarbamoyl)-3-methylsulfanyl-propyl]-carbamic acid tert-butyl ester(223648-45-1)

Safety Data

• Hazardous Substances Data: 223648-45-1(Hazardous Substances Data)

Upstream product

• 223648-39-3 1-(tert-butoxycarbonylamino)cyclohexan-1-carboxamide 
• 5241-66-7 (R)-N-(tert-butoxycarbonyl)methionine 
• 115951-16-1 1-tert-butoxycarbonylaminocyclohexanecarboxylic acid 

Downstream Products

• 223648-53-1 (S)-2-[(R)-1-(1-Carbamoyl-cyclohexyl)-2-oxo-pyrrolidin-3-ylcarbamoyl]-pyrrolidine-1-carboxylic acid benzyl ester 
• 223648-49-5 [1-(1-carbamoyl-cyclohexyl)-2-oxo-pyrrolidin-3-yl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Synthesis and dopamine receptor modulating activity of novel peptidomimetics of L-prolyl-L-leucyl-glycinamide featuring α,α- disubstituted amino acids

In the present study, L-prolyl-L-leucyl-glycinamide (1) peptidomimetics 3a-3d and 4a-4d were synthesized utilizing α,α-disubstituted amino acids. These analogues were designed to explore the conformational effects of constraints at the φ3 and ψ3 torsion angles. Constrained conformations were verified by the use of X-ray crystallography and circular dichroism. The effects of Pro-Leu-Gly-NH2 analognes 3a-3d and 4a-4d on enhancing rotational behavior induced by apomorphine in the 6-hydroxydopamine-lesioned animal models of Parkinson's disease were studied. The ability of these peptidomimetics to increase the binding of agonist N-propylnorapomorphine (NPA) to the dopamine D2 receptor was also examined. Extended analogue Pro- Leu-Deg-NH2 was the most active compound of this series. It was 10 times more potent and almost 2 times more effective than 1 in increasing apomorphine-induced rotations (56 ± 15% at 1.0 mg/kg ip) and in enhancing [3H]NPA specific binding (40%).